Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Orally active, selective 5-HT1B/1D receptor agonist. Produces a dose-dependent reduction in carotid artery blood flow in vivo. Displays antimigraine activity.
Sold for research purposes under agreement from Pfizer Inc.
Eletriptan hydrobromide is also offered as part of the Tocriscreen FDA-Approved Drugs. Find out more about compound libraries available from Tocris.
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
References are publications that support the biological activity of the product.
Napier et al (1999) Characterisation of the 5-HT receptor binding profile of eletr. and kinetics of [3H]-eletriptan binding at human 5-HT1B and 5-HT1D receptors. Eur.J.Pharmacol. 368 259 PMID: 10193663
Gupta et al (2000) The in vivo pharmacological profile of eletr. (UK-116,044): a potent and novel 5-HT(1B/1D) receptor agonist. Eur.J.Pharmacol. 398 73 PMID: 10856450
Willems et al (1998) Porcine carotid vascular effects of eletr. (UK-116,044): a new 5-HT1B/1D receptor agonist with anti-migraine activity. Naunyn-Schmied.Arch.Pharmacol. 358 212
Keywords: Eletriptan hydrobromide, Eletriptan hydrobromide supplier, 5-HT1B, 5-HT1D, 5-HT1B/1D, selective, orally, active, agonists, receptors, serotonin, Pfizer, Receptors, 3862, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for Eletriptan hydrobromide.
There are currently no reviews for this product. Be the first to review Eletriptan hydrobromide and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.